Patients with hidradenitis suppurativa (HS) are frequently undertreated, and there are few effective treatments available for this population. Biologics are a newer treatment technique that is being utilised to treat a variety of inflammatory diseases, including HS. Biologics are generally reserved for moderate-to-severe instances or those that have shown to be resistant to therapy. Despite the fact that several biologics have been tested for use in HS, only one biologic, adalimumab, is presently authorised by the US FDA for the treatment of moderate-to-severe HS.
The many scoring methods used in research studies, as well as the comparatively few well-designed, properly powered clinical trials, are limitations in the use of biologics for HS.